Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Jeffrey Bluestone, PhD

    TitleExec Vice Chancellor/Provost
    SchoolUCSF Chancellor/EVC/FAS
    DepartmentEvc&P Direct Office Activities
    Address513 Parnassus Ave, Med Sci
    San Francisco CA 94143
    Phone415-476-4451
      Other Positions
      TitleProfessor, School of Medicine


       Overview 
       Overview
      Jeffrey Bluestone, PhD, was appointed executive vice chancellor and provost at the University of California, San Francisco (UCSF), March 2010, having served in a number of posts including Director, UCSF Diabetes Center and the Immune Tolerance Network and as interim vice chancellor—research.

      As executive vice chancellor and provost, he serves as chief academic officer, guides the research and academic enterprise at UCSF, advances the campus priorities in close collaboration with the chancellor and the campus leadership team, and oversees the campus ethics and compliance enterprise.

      As interim vice chancellor—research, Dr. Bluestone directed the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He also worked to strengthen external research partnerships, particularly with industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

      In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

      Dr. Bluestone, who holds the A.W. and Mary Margaret Clausen Distinguished Professorship in Metabolism and Endocrinology and is current director of the Hormone Research Institute, joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center to focus on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.

      As a scientist, Dr. Bluestone’s research has helped clarify the body’s immune response on a molecular level. His research has catalyzed recent progress in stem cell research, islet cell transplantation and immune tolerance therapies – research that has formidably translated into drugs to treat human disease.

      Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.

      Prior to joining UCSF, Bluestone was at the University of Chicago, where he was a member of the Ben May Institute for Cancer Research, rising over 13 years from an associate professor to the director of the institute. He had previously worked for seven years in various roles at the National Cancer Institute of the National Institutes of Health, ultimately becoming a senior investigator in the Immunology Branch of the National Cancer Institute.

      Bluestone earned both his BS in biology and his MS in microbiology from Rutgers State University, and his PhD in immunology from the Cornell Graduate School of Medical Science (Sloan-Kettering Division).


       ORNG Applications 
       Websites
       Featured Videos
       In The News
       Awarded Grants
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-Driven Activation Induces Instability of Regulatory T Cells during an Inflammatory Autoimmune Response. Immunity. 2013 Nov 14; 39(5):949-62.
        View in: PubMed
      2. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013 Nov; 3(11).
        View in: PubMed
      3. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, Tang Q. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant. 2013 Nov; 13(11):3010-20.
        View in: PubMed
      4. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013; 4:232.
        View in: PubMed
      5. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19.
        View in: PubMed
      6. Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA. Production of a-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol. 2013 Jul; 11(7):e1001610.
        View in: PubMed
      7. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605.
        View in: PubMed
      8. Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone JA. Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. J Autoimmun. 2013 Sep; 45:58-67.
        View in: PubMed
      9. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74.
        View in: PubMed
      10. Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 2013 Aug; 62(8):2870-8.
        View in: PubMed
      11. Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT. The microRNA cluster miR-17~92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013 Aug; 14(8):840-8.
        View in: PubMed
      12. Jeker LT, Zhou X, Blelloch R, Bluestone JA. DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability. PLoS One. 2013; 8(5):e66282.
        View in: PubMed
      13. Jeker LT, Bluestone JA. MicroRNA regulation of T-cell differentiation and function. Immunol Rev. 2013 May; 253(1):65-81.
        View in: PubMed
      14. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013 Apr 3; 5(179):179ps7.
        View in: PubMed
      15. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013 Apr; 14(4):307-8.
        View in: PubMed
      16. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Apr; 13(4):243-56.
        View in: PubMed
      17. Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF. Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. J Immunol. 2013 May 1; 190(9):4470-3.
        View in: PubMed
      18. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. Immune therapy and ß-cell death in type 1 diabetes. Diabetes. 2013 May; 62(5):1676-80.
        View in: PubMed
      19. Stumpf M, Zhou X, Bluestone JA. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol. 2013 Feb 1; 190(3):961-9.
        View in: PubMed
      20. Bluestone JA, Bour-Jordan H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol. 2012 Nov; 4(11).
        View in: PubMed
      21. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 56(2):391-400.
        View in: PubMed
      22. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67.
        View in: PubMed
      23. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012 Sep 24; 209(10):1713-22, S1-19.
        View in: PubMed
      24. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett. 2012 Aug 8; 12(8):4018-24.
        View in: PubMed
      25. Bluestone JA, Small EJ. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8.
        View in: PubMed
      26. Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12668-73.
        View in: PubMed
      27. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function. Diabetes. 2012 Sep; 61(9):2340-8.
        View in: PubMed
      28. Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA. MicroRNA 10a marks regulatory T cells. PLoS One. 2012; 7(5):e36684.
        View in: PubMed
      29. Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS One. 2012; 7(4):e36011.
        View in: PubMed
      30. Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone JA, Srivastava D, McManus MT. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep. 2012 Apr 19; 1(4):385-91.
        View in: PubMed
      31. Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a007807.
        View in: PubMed
      32. Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012 Feb; 4(1):11-21.
        View in: PubMed
      33. Bluestone JA. The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med. 2011 Dec 1; 365(22):2129-31.
        View in: PubMed
      34. Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y, Irie J, Bluestone JA, Itoh H. A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse. J Immunol. 2011 Nov 15; 187(10):4947-53.
        View in: PubMed
      35. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol. 2011 Oct 1; 187(7):3466-74.
        View in: PubMed
      36. Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone JA, Barry SC, Sparwasser T, Riley JL, Schultze JL. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol. 2011 Sep; 12(9):898-907.
        View in: PubMed
      37. Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med. 2011 Aug 10; 3(95):95fs1.
        View in: PubMed
      38. Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA. Control of TH17 cells occurs in the small intestine. Nature. 2011 Jul 28; 475(7357):514-8.
        View in: PubMed
      39. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol. 2011 Aug 15; 187(4):2015-22.
        View in: PubMed
      40. Bailey-Bucktrout SL, Bluestone JA. Regulatory T cells: stability revisited. Trends Immunol. 2011 Jul; 32(7):301-6.
        View in: PubMed
      41. Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O, Christensen M, Moody V, Steward CA, Mohammed JP, Fusakio ME, Masteller EL, Finger EB, Houchins JP, Naf D, Koentgen F, Ridgway WM, Todd JA, Bluestone JA, Peterson LB, Mattner J, Wicker LS. Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. J Immunol. 2011 Jul 1; 187(1):325-36.
        View in: PubMed
      42. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/?B7 family. Immunol Rev. 2011 May; 241(1):180-205.
        View in: PubMed
      43. Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or ß-cell suicide revisited. Diabetes. 2011 May; 60(5):1370-9.
        View in: PubMed
      44. Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011 May; 241(1):5-19.
        View in: PubMed
      45. Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM. Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. J Surg Res. 2011 Jul; 169(1):e69-75.
        View in: PubMed
      46. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011 Apr 1; 186(7):3918-26.
        View in: PubMed
      47. Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol. 2011 Apr 1; 186(7):3831-5.
        View in: PubMed
      48. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One. 2011; 6(1):e15868.
        View in: PubMed
      49. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601.
        View in: PubMed
      50. Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, Sheppard D. Expression of avß8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest. 2010 Dec; 120(12):4436-44.
        View in: PubMed
      51. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010 Nov; 10(11):797-803.
        View in: PubMed
      52. Sonn CH, Yu YB, Hong YJ, Shim YJ, Bluestone JA, Min BH, Lee KM. Clusterin synergizes with IL-2 for the expansion and IFN-? production of natural killer cells. J Leukoc Biol. 2010 Nov; 88(5):955-63.
        View in: PubMed
      53. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010 Aug 30; 207(9):1871-8.
        View in: PubMed
      54. Turka LA, Wood K, Bluestone JA. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant. 2010 Aug; 15(4):441-8.
        View in: PubMed
      55. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010 Aug; 10(8):1870-80.
        View in: PubMed
      56. Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone JA, Lee KM. FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol. 2010 Dec; 88(6):1089-97.
        View in: PubMed
      57. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010; 5(7):e11726.
        View in: PubMed
      58. Shoda L, Kreuwel H, Gadkar K, Zheng Y, Whiting C, Atkinson M, Bluestone J, Mathis D, Young D, Ramanujan S. The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin Exp Immunol. 2010 Aug; 161(2):250-67.
        View in: PubMed
      59. Jeker LT, Bluestone JA. Small RNA regulators of T cell-mediated autoimmunity. J Clin Immunol. 2010 May; 30(3):347-57.
        View in: PubMed
      60. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010 Apr 29; 464(7293):1293-300.
        View in: PubMed
      61. Kim TJ, Kim N, Kim EO, Choi JR, Bluestone JA, Lee KM. Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology. 2010 Aug; 130(4):545-55.
        View in: PubMed
      62. Penaranda C, Tang Q, Ruddle NH, Bluestone JA. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes. 2010 Jun; 59(6):1461-8.
        View in: PubMed
      63. Bluestone JA, Krensky AM, Turka LA, Rotrosen D, Matthews JB. Ten years of the Immune Tolerance Network: an integrated clinical research organization. Sci Transl Med. 2010 Feb 17; 2(19):19cm7.
        View in: PubMed
      64. Brusko TM, Bluestone JA. Regulatory T cells directed to the site of the action. Proc Natl Acad Sci U S A. 2009 Dec 8; 106(49):20553-4.
        View in: PubMed
      65. Bluestone JA, Kuchroo V. Autoimmunity. Curr Opin Immunol. 2009 Dec; 21(6):579-81.
        View in: PubMed
      66. Penaranda C, Bluestone JA. Is antigen specificity of autoreactive T cells the key to islet entry? Immunity. 2009 Oct 16; 31(4):534-6.
        View in: PubMed
      67. Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009 Nov; 9(11):811-6.
        View in: PubMed
      68. Bour-Jordan H, Bluestone JA. How suppressor cells led to anergy, costimulation, and beyond. J Immunol. 2009 Oct 1; 183(7):4147-9.
        View in: PubMed
      69. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5.
        View in: PubMed
      70. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009 Nov; 10(11):1185-92.
        View in: PubMed
      71. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 Sep; 10(9):1000-7.
        View in: PubMed
      72. Norquay LD, D'Aquino KE, Opare-Addo LM, Kuznetsova A, Haas M, Bluestone JA, White MF. Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice. Endocrinology. 2009 Oct; 150(10):4531-40.
        View in: PubMed
      73. Perruche S, Zhang P, Maruyama T, Bluestone JA, Saas P, Chen W. Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol. 2009 Jul 15; 183(2):953-61.
        View in: PubMed
      74. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009 Jul 1; 183(1):75-82.
        View in: PubMed
      75. Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut. 2009 Oct; 58(10):1363-73.
        View in: PubMed
      76. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009 Jun; 21(3):281-5.
        View in: PubMed
      77. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73.
        View in: PubMed
      78. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev. 2009 May; 229(1):41-66.
        View in: PubMed
      79. Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, Rosenthal WL, Anderson MS, Bour-Jordan H, Bluestone JA. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med. 2009 Mar 16; 206(3):507-14.
        View in: PubMed
      80. Su MA, Stenerson M, Liu W, Putnam A, Conte F, Bluestone JA, Anderson MS. The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients. Clin Immunol. 2009 Apr; 131(1):139-44.
        View in: PubMed
      81. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009 Mar; 58(3):652-62.
        View in: PubMed
      82. You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci. 2008 Dec; 1150:300-10.
        View in: PubMed
      83. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 2; 105(48):18895-900.
        View in: PubMed
      84. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008 Oct; 8(10):2086-96.
        View in: PubMed
      85. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008 Oct 23; 455(7216):1109-13.
        View in: PubMed
      86. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008 Sep 1; 205(9):1983-91.
        View in: PubMed
      87. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol. 2008 Nov; 28(6):677-84.
        View in: PubMed
      88. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24.
        View in: PubMed
      89. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug; 224:166-82.
        View in: PubMed
      90. Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol. 2008 Jun 15; 180(12):7793-803.
        View in: PubMed
      91. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev. 2008 Jun; 223:371-90.
        View in: PubMed
      92. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008 May; 28(5):687-97.
        View in: PubMed
      93. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008 May; 14(5):528-35.
        View in: PubMed
      94. Brusko T, Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol. 2008 Apr; 38(4):931-4.
        View in: PubMed
      95. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008 Mar; 9(3):239-44.
        View in: PubMed
      96. Bluestone JA, Hebrok M. Safer, longer-lasting regulatory T cells with beta-catenin. Nat Med. 2008 Feb; 14(2):118-9.
        View in: PubMed
      97. Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes. 2008 Apr; 57(4):958-66.
        View in: PubMed
      98. Bour-Jordan H, Bluestone JA. B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest. 2007 Dec; 117(12):3642-5.
        View in: PubMed
      99. Szot GL, Koudria P, Bluestone JA. Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp. 2007; (9):404.
        View in: PubMed
      100. Szot GL, Koudria P, Bluestone JA. Murine pancreatic islet isolation. J Vis Exp. 2007; (7):255.
        View in: PubMed
      101. Bluestone JA. Regulatory T cells: therapeutic potential for treating transplant rejection and type I diabetes. J Vis Exp. 2007; (7):257.
        View in: PubMed
      102. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 2007 Sep 20; 449(7160):361-5.
        View in: PubMed
      103. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 2007 Nov; 148(11):5136-44.
        View in: PubMed
      104. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol. 2007 Aug; 7(8):650-4.
        View in: PubMed
      105. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007 Aug; 7(8):622-32.
        View in: PubMed
      106. Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol. 2007 Jul 15; 179(2):1004-12.
        View in: PubMed
      107. Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007 Oct; 125(1):16-25.
        View in: PubMed
      108. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant. 2007 Jun; 7(6):1457-63.
        View in: PubMed
      109. Chikuma S, Bluestone JA. Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol. 2007 May; 37(5):1285-9.
        View in: PubMed
      110. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6335-40.
        View in: PubMed
      111. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J. New reagents on the horizon for immune tolerance. Annu Rev Med. 2007; 58:329-46.
        View in: PubMed
      112. Bour-Jordan H, Bluestone JA. Sensory neurons link the nervous system and autoimmune diabetes. Cell. 2006 Dec 15; 127(6):1097-9.
        View in: PubMed
      113. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006 Nov 27; 203(12):2737-47.
        View in: PubMed
      114. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28; 355(13):1318-30.
        View in: PubMed
      115. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep; 55(9):2588-94.
        View in: PubMed
      116. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006 Aug; 212:217-37.
        View in: PubMed
      117. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006 Aug 1; 177(3):1451-9.
        View in: PubMed
      118. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest. 2006 Aug; 116(8):2252-61.
        View in: PubMed
      119. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006 Jul 10; 203(7):1701-11.
        View in: PubMed
      120. Tang Q, Bluestone JA. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol. 2006 Jun; 7(6):551-3.
        View in: PubMed
      121. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006 May; 116(5):1371-81.
        View in: PubMed
      122. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006 Mar; 24(3):233-8.
        View in: PubMed
      123. Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol. 2006 Apr; 18(2):103-10.
        View in: PubMed
      124. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006 Jan; 7(1):83-92.
        View in: PubMed
      125. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005 Nov 21; 202(10):1375-86.
        View in: PubMed
      126. Bour-Jordan H, Thompson HL, Bluestone JA. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol. 2005 Nov 1; 175(9):5649-55.
        View in: PubMed
      127. Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005 Dec; 17(6):638-42.
        View in: PubMed
      128. Dai YD, Jensen KP, Lehuen A, Masteller EL, Bluestone JA, Wilson DB, Sercarz EE. A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas. J Immunol. 2005 Sep 15; 175(6):3621-7.
        View in: PubMed
      129. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct; 115(10):2904-13.
        View in: PubMed
      130. Chen W, Bluestone JA, Herold KC. Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol. 2005 Sep-Dec; 24(5-6):287-305.
        View in: PubMed
      131. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol. 2005 Sep 1; 175(5):3053-9.
        View in: PubMed
      132. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005 Aug; 23(2):115-26.
        View in: PubMed
      133. Chikuma S, Abbas AK, Bluestone JA. B7-independent inhibition of T cells by CTLA-4. J Immunol. 2005 Jul 1; 175(1):177-81.
        View in: PubMed
      134. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9.
        View in: PubMed
      135. Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol. 2005 May 1; 174(9):5298-305.
        View in: PubMed
      136. Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach JF, Bluestone JA, Miller SD. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol. 2005 Apr 15; 174(8):4525-34.
        View in: PubMed
      137. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol. 2005 Apr 15; 174(8):4696-705.
        View in: PubMed
      138. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol. 2005 Apr; 115(1):3-9.
        View in: PubMed
      139. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005 Apr; 5(4):343-9.
        View in: PubMed
      140. Bluestone JA. CTLA-4Ig is finally making it: a personal perspective. Am J Transplant. 2005 Mar; 5(3):423-4.
        View in: PubMed
      141. Boehm BO, Bluestone JA. Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus. Rev Diabet Stud. 2004; 1(4):156-64.
        View in: PubMed
      142. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005; 23:447-85.
        View in: PubMed
      143. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004 Nov; 34(11):2996-3005.
        View in: PubMed
      144. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest. 2004 Oct; 114(7):979-87.
        View in: PubMed
      145. Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone JA, Sarvetnick N, Wilson DB. Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clin Immunol. 2004 Oct; 113(1):29-37.
        View in: PubMed
      146. Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A. 2004 Oct 5; 101 Suppl 2:14622-6.
        View in: PubMed
      147. Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone JA, Miller SD. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J Immunol. 2004 Jun 15; 172(12):7442-50.
        View in: PubMed
      148. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004 Jun 7; 199(11):1455-65.
        View in: PubMed
      149. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 2004 Jun; 20(6):757-67.
        View in: PubMed
      150. Robey EA, Bluestone JA. Notch signaling in lymphocyte development and function. Curr Opin Immunol. 2004 Jun; 16(3):360-6.
        View in: PubMed
      151. Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA. Notch 1 signaling regulates peripheral T cell activation. Immunity. 2004 Apr; 20(4):407-15.
        View in: PubMed
      152. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004 Mar; 4(3):390-401.
        View in: PubMed
      153. Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol. 2004 Feb 1; 172(3):1449-54.
        View in: PubMed
      154. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33.
        View in: PubMed
      155. Stock PG, Bluestone JA. Beta-cell replacement for type I diabetes. Annu Rev Med. 2004; 55:133-56.
        View in: PubMed
      156. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol. 2003 Nov 15; 171(10):5587-95.
        View in: PubMed
      157. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol. 2003 Oct 1; 171(7):3348-52.
        View in: PubMed
      158. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003 Sep; 9(9):1202-8.
        View in: PubMed
      159. Park CG, Thiex NW, Lee KM, Szot GL, Bluestone JA, Lee KD. Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res. 2003 Aug; 20(8):1239-48.
        View in: PubMed
      160. Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant. 2003 Jul; 3(7):794-803.
        View in: PubMed
      161. Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone JA, Granstein RD. Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. J Clin Invest. 2003 Jun; 111(12):1923-31.
        View in: PubMed
      162. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003 Mar; 3(3):253-7.
        View in: PubMed
      163. Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J Immunol. 2003 Feb 1; 170(3):1510-6.
        View in: PubMed
      164. Starwalt SE, Masteller EL, Bluestone JA, Kranz DM. Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng. 2003 Feb; 16(2):147-56.
        View in: PubMed
      165. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003 Feb; 111(3):409-18.
        View in: PubMed
      166. Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol. 2003 Feb; 4(2):182-8.
        View in: PubMed
      167. Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003 Jan 6; 197(1):129-35.
        View in: PubMed
      168. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003 Jan; 18(1):41-51.
        View in: PubMed
      169. Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp. 2003; 252:55-63; discussion 63-6, 106-14.
        View in: PubMed
      170. Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol Res. 2003; 28(3):241-53.
        View in: PubMed
      171. Finger EB, Bluestone JA. When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol. 2002 Nov; 3(11):1056-7.
        View in: PubMed
      172. Masteller EL, Bluestone JA. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol. 2002 Oct; 14(5):652-9.
        View in: PubMed
      173. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13.
        View in: PubMed
      174. Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7.
        View in: PubMed
      175. Rotrosen D, Matthews JB, Bluestone JA. The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol. 2002 Jul; 110(1):17-23.
        View in: PubMed
      176. Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct antigen presentation. Am J Transplant. 2002 Jul; 2(6):510-9.
        View in: PubMed
      177. Chikuma S, Bluestone JA. CTLA-4: acting at the synapse. Mol Interv. 2002 Jul; 2(4):205-8.
        View in: PubMed
      178. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8.
        View in: PubMed
      179. Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol. 2002 May 1; 168(9):4480-7.
        View in: PubMed
      180. Eagar TN, Karandikar NJ, Bluestone JA, Miller SD. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol. 2002 Apr; 32(4):972-81.
        View in: PubMed
      181. Salomon B, Rhee L, Bour-Jordan H, Hsin H, Montag A, Soliven B, Arcella J, Girvin AM, Padilla J, Miller SD, Bluestone JA. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med. 2001 Sep 3; 194(5):677-84.
        View in: PubMed
      182. O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 1; 167(5):2555-60.
        View in: PubMed
      183. Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest. 2001 Sep; 108(6):895-903.
        View in: PubMed
      184. Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AI. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunol. 2001 Aug 15; 167(4):1996-2003.
        View in: PubMed
      185. Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum. 2001 Aug; 44(8):1730-5.
        View in: PubMed
      186. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells--they're back and critical for regulation of autoimmunity! Immunol Rev. 2001 Aug; 182:149-63.
        View in: PubMed
      187. Sperling AI, Bluestone JA. ICOS costimulation: It's not just for TH2 cells anymore. Nat Immunol. 2001 Jul; 2(7):573-4.
        View in: PubMed
      188. Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA, Fu YX. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med. 2001 Jun 4; 193(11):1327-32.
        View in: PubMed
      189. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001 Jun; 21(6):1011-6.
        View in: PubMed
      190. Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB. Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol. 2001 Jun 1; 166(11):6491-9.
        View in: PubMed
      191. Bluestone JA, Matthews J. The Immune Tolerance Network: tolerance at the crossroads. Philos Trans R Soc Lond B Biol Sci. 2001 May 29; 356(1409):773-6.
        View in: PubMed
      192. Szot GL, Zhou P, Rulifson I, Wang J, Guo Z, Kim O, Newel KA, Thistlethwaite JR, Bluestone JA, Alegre ML. Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice. Am J Transplant. 2001 May; 1(1):38-46.
        View in: PubMed
      193. Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J. Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
        View in: PubMed
      194. Zhou P, Szot G, Guo Z, Kim O, He G, Wang J, Grusby M, Newell K, Thistlethwaite J, Bluestone J, Alegre M. Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig. Transplant Proc. 2001 Feb-Mar; 33(1-2):214-6.
        View in: PubMed
      195. Griffin MD, Holman PO, Tang Q, Ashourian N, Korthäuer U, Kranz DM, Bluestone JA. Development and applications of surface-linked single chain antibodies against T-cell antigens. J Immunol Methods. 2001 Feb 1; 248(1-2):77-90.
        View in: PubMed
      196. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001; 19:225-52.
        View in: PubMed
      197. Zhou P, Szot GL, Guo Z, Kim O, He G, Wang J, Grusby MJ, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre ML. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol. 2000 Nov 15; 165(10):5580-7.
        View in: PubMed
      198. Bluestone JA, Matthews JB, Krensky AM. The immune tolerance network: the "Holy Grail" comes to the clinic. J Am Soc Nephrol. 2000 Nov; 11(11):2141-6.
        View in: PubMed
      199. Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 2000 Sep 22; 109(2):173-80.
        View in: PubMed
      200. Neville KL, Dal Canto MC, Bluestone JA, Miller SD. CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease. J Virol. 2000 Sep; 74(18):8349-57.
        View in: PubMed
      201. Bluestone JA, Matthews JB. The immune tolerance network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin Immunol. 2000 Sep; 96(3):171-3.
        View in: PubMed
      202. Schwarz A, Beissert S, Grosse-Heitmeyer K, Gunzer M, Bluestone JA, Grabbe S, Schwarz T. Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J Immunol. 2000 Aug 15; 165(4):1824-31.
        View in: PubMed
      203. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol. 2000 Jun 15; 164(12):6230-6.
        View in: PubMed
      204. Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 1; 164(9):4433-42.
        View in: PubMed
      205. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000 Apr; 12(4):431-40.
        View in: PubMed
      206. Szot GL, Zhou P, Sharpe AH, He G, Kim O, Newell KA, Bluestone JA, Thistlethwaite JR. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival. Transplantation. 2000 Mar 15; 69(5):904-9.
        View in: PubMed
      207. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000 Feb 25; 200(1):16-26.
        View in: PubMed
      208. Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol. 2000 Jan 15; 164(2):670-8.
        View in: PubMed
      209. Korthäuer U, Nagel W, Davis EM, Le Beau MM, Menon RS, Mitchell EO, Kozak CA, Kolanus W, Bluestone JA. Anergic T lymphocytes selectively express an integrin regulatory protein of the cytohesin family. J Immunol. 2000 Jan 1; 164(1):308-18.
        View in: PubMed
      210. Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol. 2000 Jan 1; 164(1):136-43.
        View in: PubMed
      211. Beissert S, Bluestone JA, Mindt I, Voskort M, Metze D, Mehling A, Luger TA, Schwarz T, Grabbe S. Reduced ultraviolet-induced carcinogenesis in mice with a functional disruption in B7-mediated costimulation. J Immunol. 1999 Dec 15; 163(12):6725-31.
        View in: PubMed
      212. Rajagopal K, Sommers CL, Decker DC, Mitchell EO, Korthauer U, Sperling AI, Kozak CA, Love PE, Bluestone JA. RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation. J Exp Med. 1999 Dec 6; 190(11):1657-68.
        View in: PubMed
      213. Mathur M, Herrmann K, Qin Y, Gulmen F, Li X, Krimins R, Weinstock J, Elliott D, Bluestone JA, Padrid P. CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice. Am J Respir Cell Mol Biol. 1999 Oct; 21(4):498-509.
        View in: PubMed
      214. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
        View in: PubMed
      215. Newell KA, He G, Guo Z, Kim O, Szot GL, Rulifson I, Zhou P, Hart J, Thistlethwaite JR, Bluestone JA. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol. 1999 Sep 1; 163(5):2358-62.
        View in: PubMed
      216. Theriault BR, Thistlethwaite JR, Levisetti MG, Wardrip CL, Szot G, Bruce DS, Rilo H, Li X, Gray GS, Bluestone JA, Padrid PA. Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey (Macaca fascilularis). Transplantation. 1999 Aug 15; 68(3):331-7.
        View in: PubMed
      217. Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol. 1999 May 15; 162(10):5784-91.
        View in: PubMed
      218. Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res. 1999 May 1; 59(9):2096-101.
        View in: PubMed
      219. La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. J Immunol. 1999 Apr 15; 162(8):4817-23.
        View in: PubMed
      220. Punch JD, Lin J, Bluestone J, Bromberg JS. CD2 and CD3 receptor-mediated tolerance: constraints on T cell activation. Transplantation. 1999 Mar 15; 67(5):741-8.
        View in: PubMed
      221. Sciammas R, Bluestone JA. TCRgammadelta cells and viruses. Microbes Infect. 1999 Mar; 1(3):203-12.
        View in: PubMed
      222. Guehler SR, Bluestone JA, Barrett TA. Activation and peripheral expansion of murine T-cell receptor gamma delta intraepithelial lymphocytes. Gastroenterology. 1999 Feb; 116(2):327-34.
        View in: PubMed
      223. Chuang E, Lee KM, Robbins MD, Duerr JM, Alegre ML, Hambor JE, Neveu MJ, Bluestone JA, Thompson CB. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol. 1999 Feb 1; 162(3):1270-7.
        View in: PubMed
      224. Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C. The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod. 1999 Jan; 5(1):84-7.
        View in: PubMed
      225. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular basis of T cell inactivation by CTLA-4. Science. 1998 Dec 18; 282(5397):2263-6.
        View in: PubMed
      226. La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J Immunol. 1998 Dec 15; 161(12):6552-8.
        View in: PubMed
      227. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998 Dec 1; 58(23):5301-4.
        View in: PubMed
      228. Salomon B, Bluestone JA. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol. 1998 Nov 15; 161(10):5138-42.
        View in: PubMed
      229. Sciammas R, Bluestone JA. HSV-1 glycoprotein I-reactive TCR gamma delta cells directly recognize the peptide backbone in a conformationally dependent manner. J Immunol. 1998 Nov 15; 161(10):5187-92.
        View in: PubMed
      230. Cantrell D, Bluestone J, Vivier E, Tybulewicz V. Signalling through the TCR. Res Immunol. 1998 Nov-Dec; 149(9):866-7.
        View in: PubMed
      231. Bluestone JA. Cell fate in the immune system: decisions, decisions, decisions. Immunol Rev. 1998 Oct; 165:5-12.
        View in: PubMed
      232. Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J Neuroimmunol. 1998 Aug 14; 89(1-2):10-8.
        View in: PubMed
      233. Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol. 1998 Aug 1; 161(3):1516-24.
        View in: PubMed
      234. Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998 Aug; 164:63-72.
        View in: PubMed
      235. Karandikar NJ, Vanderlugt CL, Eagar T, Tan L, Bluestone JA, Miller SD. Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis. J Immunol. 1998 Jul 1; 161(1):192-9.
        View in: PubMed
      236. Guehler SR, Finch RJ, Bluestone JA, Barrett TA. Increased threshold for TCR-mediated signaling controls self reactivity of intraepithelial lymphocytes. J Immunol. 1998 Jun 1; 160(11):5341-6.
        View in: PubMed
      237. Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 1998 Jun; 30(4):1369-70.
        View in: PubMed
      238. Chau LA, Bluestone JA, Madrenas J. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J Exp Med. 1998 May 18; 187(10):1699-709.
        View in: PubMed
      239. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol. 1998 May 15; 160(10):4841-9.
        View in: PubMed
      240. Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol. 1998 Apr 15; 160(8):3855-60.
        View in: PubMed
      241. Padrid PA, Mathur M, Li X, Herrmann K, Qin Y, Cattamanchi A, Weinstock J, Elliott D, Sperling AI, Bluestone JA. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma. Am J Respir Cell Mol Biol. 1998 Apr; 18(4):453-62.
        View in: PubMed
      242. Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J Immunol. 1998 Feb 15; 160(4):1866-74.
        View in: PubMed
      243. Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR, Bluestone JA. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997 Dec 1; 159(11):5187-91.
        View in: PubMed
      244. Herold KC, Lu J, Rulifson I, Vezys V, Taub D, Grusby MJ, Bluestone JA. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol. 1997 Nov 1; 159(9):4150-3.
        View in: PubMed
      245. Vanderlugt CL, Karandikar NJ, Lenschow DJ, Dal Canto MC, Bluestone JA, Miller SD. Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. J Neuroimmunol. 1997 Nov; 79(2):113-8.
        View in: PubMed
      246. Lechler R, Bluestone JA. Transplantation tolerance--putting the pieces together. Curr Opin Immunol. 1997 Oct; 9(5):631-3.
        View in: PubMed
      247. Smith JA, Bluestone JA. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol. 1997 Oct; 9(5):648-54.
        View in: PubMed
      248. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 1997 Sep 15; 57(18):4036-41.
        View in: PubMed
      249. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 1997 Jul 21; 186(2):229-38.
        View in: PubMed
      250. Sperling AI, Decker DC, DiPaolo RJ, Stern DA, Shum A, Bluestone JA. Selective expansion of Vgamma2-Vdelta7 TCR gammadelta cells in C57BL/6 mice is postnatal and extrathymic. J Immunol. 1997 Jul 1; 159(1):86-91.
        View in: PubMed
      251. Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA. T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. J Exp Med. 1997 Jun 2; 185(11):1969-75.
        View in: PubMed
      252. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med. 1997 Apr 21; 185(8):1413-22.
        View in: PubMed
      253. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol. 1997 Mar 1; 158(5):1989-93.
        View in: PubMed
      254. Woodle ES, Smith DM, Bluestone JA, Kirkman WM, Green DR, Skowronski EW. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J Immunol. 1997 Mar 1; 158(5):2156-64.
        View in: PubMed
      255. Herold KG, Lenschow DJ, Bluestone JA. CD28/B7 regulation of autoimmune diabetes. Immunol Res. 1997 Feb; 16(1):71-84.
        View in: PubMed
      256. Woodle ES, Smith DM, Bluestone JA, Green DR, Skowronski EW. Class I MHC mediates programmed cell death in a Fas-independent manner. Transplant Proc. 1997 Feb-Mar; 29(1-2):1101.
        View in: PubMed
      257. Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med. 1997 Jan 20; 185(2):219-29.
        View in: PubMed
      258. Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA. CD28 costimulation promotes the production of Th2 cytokines. J Immunol. 1997 Jan 15; 158(2):658-65.
        View in: PubMed
      259. Herold KC, Vezys V, Koons A, Lenschow D, Thompson C, Bluestone JA. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1997 Jan 15; 158(2):984-91.
        View in: PubMed
      260. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol. 1996 Nov 1; 157(9):3909-17.
        View in: PubMed
      261. Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev. 1996 Oct; 153:155-82.
        View in: PubMed
      262. Khattri R, Sperling AI, Qian D, Fitch FW, Shores EW, Love PE, Bluestone JA. TCR-gamma delta cells in CD3 zeta-deficient mice contain Fc epsilon RI gamma in the receptor complex but are specifically unresponsive to antigen. J Immunol. 1996 Sep 15; 157(6):2320-7.
        View in: PubMed
      263. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 1996 Sep; 5(3):285-93.
        View in: PubMed
      264. Guehler SR, Bluestone JA, Barrett TA. Immune deviation of 2C transgenic intraepithelial lymphocytes in antigen-bearing hosts. J Exp Med. 1996 Aug 1; 184(2):493-503.
        View in: PubMed
      265. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med. 1996 Aug 1; 184(2):783-8.
        View in: PubMed
      266. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, Wang Y, Walunas T, Bluestone J, Listman J, Finn PW. Regulation of CTLA-4 expression during T cell activation. J Immunol. 1996 Jun 1; 156(11):4154-9.
        View in: PubMed
      267. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996 Jun 1; 183(6):2541-50.
        View in: PubMed
      268. Blazar BR, Taylor PA, Bluestone JA, Vallera DA. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens. Blood. 1996 May 15; 87(10):4463-72.
        View in: PubMed
      269. Woodle ES, Hussein S, Bluestone JA. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells. Transplantation. 1996 Mar 15; 61(5):798-803.
        View in: PubMed
      270. La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol Immunother. 1996 Mar; 42(3):161-9.
        View in: PubMed
      271. Bluestone JA. Costimulation and its role in organ transplantation. Clin Transplant. 1996 Feb; 10(1 Pt 2):104-9.
        View in: PubMed
      272. Walunas TL, Sperling AI, Khattri R, Thompson CB, Bluestone JA. CD28 expression is not essential for positive and negative selection of thymocytes or peripheral T cell tolerance. J Immunol. 1996 Feb 1; 156(3):1006-13.
        View in: PubMed
      273. Nishimura H, Hiromatsu K, Kobayashi N, Grabstein KH, Paxton R, Sugamura K, Bluestone JA, Yoshikai Y. IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection. J Immunol. 1996 Jan 15; 156(2):663-9.
        View in: PubMed
      274. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, Vallera DA. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens. Blood. 1996 Jan 15; 87(2):827-37.
        View in: PubMed
      275. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996; 14:233-58.
        View in: PubMed
      276. Miller SD, Vanderlugt CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 1995 Dec; 3(6):739-45.
        View in: PubMed
      277. Lenschow DJ, Zeng Y, Hathcock KS, Zuckerman LA, Freeman G, Thistlethwaite JR, Gray GS, Hodes RJ, Bluestone JA. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation. 1995 Nov 27; 60(10):1171-8.
        View in: PubMed
      278. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995 Nov; 3(5):541-7.
        View in: PubMed
      279. Bluestone JA, Lechler RI. Transplantation. Curr Opin Immunol. 1995 Oct; 7(5):617-9.
        View in: PubMed
      280. Barrett TA, Bluestone JA. Development of TCR gamma delta iIELs. Semin Immunol. 1995 Oct; 7(5):299-305.
        View in: PubMed
      281. Kaliyaperumal A, Falchetto R, Cox A, Dick R, Shabanowitz J, Chien YH, Matis L, Hunt DF, Bluestone JA. Functional expression and recognition of nonclassical MHC class I T10b is not peptide-dependent. J Immunol. 1995 Sep 1; 155(5):2379-86.
        View in: PubMed
      282. Walunas TL, Bruce DS, Dustin L, Loh DY, Bluestone JA. Ly-6C is a marker of memory CD8+ T cells. J Immunol. 1995 Aug 15; 155(4):1873-83.
        View in: PubMed
      283. Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, Bluestone JA. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 1995 Aug 1; 155(3):1544-55.
        View in: PubMed
      284. Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol. 1995 Aug 1; 155(3):1032-6.
        View in: PubMed
      285. Sperling AI, Green JM, Mosley RL, Smith PL, DiPaolo RJ, Klein JR, Bluestone JA, Thompson CB. CD43 is a murine T cell costimulatory receptor that functions independently of CD28. J Exp Med. 1995 Jul 1; 182(1):139-46.
        View in: PubMed
      286. Sandor M, Sperling AI, Cook GA, Weinstock JV, Lynch RG, Bluestone JA. Two waves of gamma delta T cells expressing different V delta genes are recruited into schistosome-induced liver granulomas. J Immunol. 1995 Jul 1; 155(1):275-84.
        View in: PubMed
      287. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 1995 Jun; 2(6):555-9.
        View in: PubMed
      288. Green JM, Noel PJ, Sperling AI, Walunas TL, Lenschow DJ, Stack R, Gray GS, Bluestone JA, Thompson CB. T cell costimulation through the CD28 receptor. Proc Assoc Am Physicians. 1995 Apr; 107(1):41-6.
        View in: PubMed
      289. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995 Mar 1; 181(3):1145-55.
        View in: PubMed
      290. Smith DM, Bluestone JA, Thistlethwaite JR, Woodle ES. Inhibition of T-cell activation by an anti-human class I MHC reactive monoclonal antibody occurs at a point distal to TCR-CD3 mediated signal transduction. Transplant Proc. 1995 Feb; 27(1):395-7.
        View in: PubMed
      291. Hu Q, Davidson D, Schwartzberg PL, Macchiarini F, Lenardo MJ, Bluestone JA, Matis LA. Identification of Rlk, a novel protein tyrosine kinase with predominant expression in the T cell lineage. J Biol Chem. 1995 Jan 27; 270(4):1928-34.
        View in: PubMed
      292. DeLuca D, Bluestone JA, Shultz LD, Sharrow SO, Tatsumi Y. Programmed differentiation of murine thymocytes during fetal thymus organ culture. J Immunol Methods. 1995 Jan 13; 178(1):13-29.
        View in: PubMed
      293. Alegre ML, Lenschow DJ, Bluestone JA. Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors. Dig Dis Sci. 1995 Jan; 40(1):58-64.
        View in: PubMed
      294. Bluestone JA, Khattri R, Sciammas R, Sperling AI. TCR gamma delta cells: a specialized T-cell subset in the immune system. Annu Rev Cell Dev Biol. 1995; 11:307-53.
        View in: PubMed
      295. Mokyr MB, Prokhorova A, Rubin M, Bluestone JA. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication. J Immunol. 1994 Oct 1; 153(7):3123-34.
        View in: PubMed
      296. Zeng Y, Gage A, Montag A, Rothlein R, Thistlethwaite JR, Bluestone JA. Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies. Transplantation. 1994 Sep 27; 58(6):681-9.
        View in: PubMed
      297. Alegre ML, Peterson LJ, Jeyarajah DR, Weiser M, Bluestone JA, Thistlethwaite JR. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J Immunol. 1994 Sep 15; 153(6):2738-49.
        View in: PubMed
      298. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1994 Sep; 1(6):501-8.
        View in: PubMed
      299. Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol. 1994 Sep 1; 153(5):1990-7.
        View in: PubMed
      300. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994 Aug; 1(5):405-13.
        View in: PubMed
      301. Smith DM, Bluestone JA, Jeyarajah DR, Newberg MH, Engelhard VH, Thistlethwaite JR, Woodle ES. Inhibition of T cell activation by a monoclonal antibody reactive against the alpha 3 domain of human MHC class I molecules. J Immunol. 1994 Aug 1; 153(3):1054-67.
        View in: PubMed
      302. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994 Jul; 15(7):321-31.
        View in: PubMed
      303. Alegre ML, Sattar HA, Herold KC, Smith J, Tepper MA, Bluestone JA. Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation. 1994 Jun 27; 57(12):1786-94.
        View in: PubMed
      304. Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol. 1994 Jun 15; 152(12):5723-33.
        View in: PubMed
      305. Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994 Jun 15; 57(11):1537-43.
        View in: PubMed
      306. Sciammas R, Johnson RM, Sperling AI, Brady W, Linsley PS, Spear PG, Fitch FW, Bluestone JA. Unique antigen recognition by a herpesvirus-specific TCR-gamma delta cell. J Immunol. 1994 Jun 1; 152(11):5392-7.
        View in: PubMed
      307. Zeng Y, Torres MA, Thistlethwaite JR, Montag A, Bluestone JA. Prolongation of human pancreatic islet xenografts by pretreatment of islets with anti-human ICAM-1 monoclonal antibody. Transplant Proc. 1994 Jun; 26(3):1120.
        View in: PubMed
      308. Rubin M, Bluestone JA, Newell KA, Prokhorova A, Mokyr MB. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases. J Immunol. 1994 Apr 1; 152(7):3522-9.
        View in: PubMed
      309. Schild H, Mavaddat N, Litzenberger C, Ehrich EW, Davis MM, Bluestone JA, Matis L, Draper RK, Chien YH. The nature of major histocompatibility complex recognition by gamma delta T cells. Cell. 1994 Jan 14; 76(1):29-37.
        View in: PubMed
      310. Sciammas R, Tatsumi Y, Sperling AI, Arunan K, Bluestone JA. TCR gamma delta cells: mysterious cells of the immune system. Immunol Res. 1994; 13(4):268-79.
        View in: PubMed
      311. Tatsumi Y, Deluca D, Cron RQ, Bluestone JA. Differential effects of T cell receptor ligation of TCR gamma delta thymocyte development in fetal thymic organ culture. Thymus. 1994-1995; 23(3-4):131-53.
        View in: PubMed
      312. Qian D, Sperling AI, Lancki DW, Tatsumi Y, Barrett TA, Bluestone JA, Fitch FW. The gamma chain of the high-affinity receptor for IgE is a major functional subunit of the T-cell antigen receptor complex in gamma delta T lymphocytes. Proc Natl Acad Sci U S A. 1993 Dec 15; 90(24):11875-9.
        View in: PubMed
      313. Peterman GM, Spencer C, Sperling AI, Bluestone JA. Role of gamma delta T cells in murine collagen-induced arthritis. J Immunol. 1993 Dec 1; 151(11):6546-58.
        View in: PubMed
      314. Sydora BC, Mixter PF, Houlden B, Hershberg R, Levy R, Comay M, Bluestone J, Kronenberg M. T-cell receptor gamma delta diversity and specificity of intestinal intraepithelial lymphocytes: analysis of IEL-derived hybridomas. Cell Immunol. 1993 Dec; 152(2):305-22.
        View in: PubMed
      315. Lenschow DJ, Su GH, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA. Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci U S A. 1993 Dec 1; 90(23):11054-8.
        View in: PubMed
      316. Sperling AI, Linsley PS, Barrett TA, Bluestone JA. CD28-mediated costimulation is necessary for the activation of T cell receptor-gamma delta+ T lymphocytes. J Immunol. 1993 Dec 1; 151(11):6043-50.
        View in: PubMed
      317. Mokyr MB, Rubin M, Newell KA, Prokhorova A, Bluestone JA. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. J Immunol. 1993 Nov 1; 151(9):4838-46.
        View in: PubMed
      318. Bluestone JA, Kaliyaperumal A, Jameson S, Miller S, Dick R. Peptide-induced changes in class I heavy chains alter allorecognition. J Immunol. 1993 Oct 15; 151(8):3943-53.
        View in: PubMed
      319. Dent AL, Matis LA, Bluestone JA, Hedrick SM. Evidence for programmed cell death of self-reactive gamma delta T cell receptor-positive thymocytes. Eur J Immunol. 1993 Oct; 23(10):2482-7.
        View in: PubMed
      320. Lenschow DJ, Bluestone JA. T cell co-stimulation and in vivo tolerance. Curr Opin Immunol. 1993 Oct; 5(5):747-52.
        View in: PubMed
      321. Tatsumi Y, Pena JC, Matis L, Deluca D, Bluestone JA. Development of T cell receptor-gamma delta cells. Phenotypic and functional correlations of T cell receptor-gamma delta thymocyte maturation. J Immunol. 1993 Sep 15; 151(6):3030-41.
        View in: PubMed
      322. Sherman LA, Chattopadhyay S, Biggs JA, Dick RF, Bluestone JA. Alloantibodies can discriminate class I major histocompatibility complex molecules associated with various endogenous peptides. Proc Natl Acad Sci U S A. 1993 Aug 1; 90(15):6949-51.
        View in: PubMed
      323. Barrett TA, Tatsumi Y, Bluestone JA. Tolerance of T cell receptor gamma/delta cells in the intestine. J Exp Med. 1993 Jun 1; 177(6):1755-62.
        View in: PubMed
      324. Sperling AI, Bluestone JA. Non-classical MHC molecules: the first line of defence? Curr Biol. 1993 May 1; 3(5):294-6.
        View in: PubMed
      325. Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. J Exp Med. 1993 Apr 1; 177(4):1061-70.
        View in: PubMed
      326. Bluestone JA, Bruce D, Peterson L, Thistlethwaite JR, Josephson M, Zeng Y, Linsley PS, Lenschow DJ. Immunosuppressive effects of anti-CD3 MAb and soluble co-stimulatory molecules. Transplant Proc. 1993 Feb; 25(1 Pt 1):546-7.
        View in: PubMed
      327. Zeng Y, Bluestone JA, Ildstad ST, Torres MA, Montag AG, Thistlethwaite RJ. Long-term functional xenograft tolerance after intrathymic islet transplantation (Lewis rat-->B6 mouse). Transplant Proc. 1993 Feb; 25(1 Pt 1):438-9.
        View in: PubMed
      328. Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier. J Immunol. 1993 Jan 1; 150(1):265-77.
        View in: PubMed
      329. Bluestone JA, Jameson S, Miller S, Dick R. Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition. J Exp Med. 1992 Dec 1; 176(6):1757-61.
        View in: PubMed
      330. Sperling AI, Cron RQ, Decker DC, Stern DA, Bluestone JA. Peripheral T cell receptor gamma delta variable gene repertoire maps to the T cell receptor loci and is influenced by positive selection. J Immunol. 1992 Nov 15; 149(10):3200-7.
        View in: PubMed
      331. Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA. Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol. 1992 Aug 15; 149(4):1124-30.
        View in: PubMed
      332. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992 Aug 7; 257(5071):789-92.
        View in: PubMed
      333. Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol. 1992 Jun 1; 148(11):3461-8.
        View in: PubMed
      334. Hiruma K, Hirsch R, Patchen M, Bluestone JA, Gress RE. Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space. Blood. 1992 Jun 1; 79(11):3050-8.
        View in: PubMed
      335. Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol. 1992 May 1; 148(9):2756-63.
        View in: PubMed
      336. Sandor M, Houlden B, Bluestone J, Hedrick SM, Weinstock J, Lynch RG. In vitro and in vivo activation of murine gamma/delta T cells induces the expression of IgA, IgM, and IgG Fc receptors. J Immunol. 1992 Apr 15; 148(8):2363-9.
        View in: PubMed
      337. Bluestone JA, Spencer C, Hirsch R. The T cell receptor in autoimmune diseases. J Rheumatol Suppl. 1992 Apr; 33:75-7.
        View in: PubMed
      338. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes. 1992 Mar; 41(3):385-91.
        View in: PubMed
      339. Fujihashi K, Taguchi T, Aicher WK, McGhee JR, Bluestone JA, Eldridge JH, Kiyono H. Immunoregulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help. J Exp Med. 1992 Mar 1; 175(3):695-707.
        View in: PubMed
      340. Johnson RM, Lancki DW, Sperling AI, Dick RF, Spear PG, Fitch FW, Bluestone JA. A murine CD4-, CD8- T cell receptor-gamma delta T lymphocyte clone specific for herpes simplex virus glycoprotein I. J Immunol. 1992 Feb 15; 148(4):983-8.
        View in: PubMed
      341. Barrett TA, Delvy ML, Kennedy DM, Lefrancois L, Matis LA, Dent AL, Hedrick SM, Bluestone JA. Mechanism of self-tolerance of gamma/delta T cells in epithelial tissue. J Exp Med. 1992 Jan 1; 175(1):65-70.
        View in: PubMed
      342. Bluestone JA, Bruce DS, Newell KA. Activation of T cells in vivo using anti-CD3 and staphylococcal enterotoxins. Int J Cancer Suppl. 1992; 7:39-41.
        View in: PubMed
      343. Hiromatsu K, Yoshikai Y, Matsuzaki G, Ohga S, Muramori K, Matsumoto K, Bluestone JA, Nomoto K. A protective role of gamma/delta T cells in primary infection with Listeria monocytogenes in mice. J Exp Med. 1992 Jan 1; 175(1):49-56.
        View in: PubMed
      344. Newell KA, Ellenhorn JD, Hirsch R, Bluestone JA. Immunopotentiation of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens. Ann N Y Acad Sci. 1991 Dec 30; 636:279-87.
        View in: PubMed
      345. Taguchi T, Aicher WK, Fujihashi K, Yamamoto M, McGhee JR, Bluestone JA, Kiyono H. Novel function for intestinal intraepithelial lymphocytes. Murine CD3+, gamma/delta TCR+ T cells produce IFN-gamma and IL-5. J Immunol. 1991 Dec 1; 147(11):3736-44.
        View in: PubMed
      346. Ferran C, Dy M, Sheehan K, Merite S, Schreiber R, Landais P, Grau G, Bluestone J, Bach JF, Chatenoud L. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release. Clin Exp Immunol. 1991 Dec; 86(3):537-43.
        View in: PubMed
      347. Kakkanaiah VN, Nagarkatti M, Bluestone JA, Nagarkatti PS. CD4-CD8- thymocytes from MRL-lpr/lpr mice exhibit abnormal proportions of alpha beta- and gamma delta-TCR+ cells and demonstrate defective responsiveness when activated through the TCR. Cell Immunol. 1991 Oct 15; 137(2):269-82.
        View in: PubMed
      348. Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach JF, Chatenoud L. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol. 1991 Oct; 21(10):2349-53.
        View in: PubMed
      349. Wells FB, Gahm SJ, Hedrick SM, Bluestone JA, Dent A, Matis LA. Requirement for positive selection of gamma delta receptor-bearing T cells. Science. 1991 Aug 23; 253(5022):903-5.
        View in: PubMed
      350. Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation. 1991 Aug; 52(2):354-60.
        View in: PubMed
      351. Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation. 1991 Aug; 52(2):361-8.
        View in: PubMed
      352. Bluestone JA, Cron RQ, Barrett TA, Houlden B, Sperling AI, Dent A, Hedrick S, Rellahan B, Matis LA. Repertoire development and ligand specificity of murine TCR gamma delta cells. Immunol Rev. 1991 Apr; 120:5-33.
        View in: PubMed
      353. Matis LA, Bluestone JA. Specificity of gamma delta receptor bearing T cells. Semin Immunol. 1991 Mar; 3(2):75-80.
        View in: PubMed
      354. Newell KA, Ellenhorn JD, Bruce DS, Bluestone JA. In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc Natl Acad Sci U S A. 1991 Feb 1; 88(3):1074-8.
        View in: PubMed
      355. Hirsch R, Bluestone JA, Bare CV, Gress RE. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant Proc. 1991 Feb; 23(1 Pt 1):270-1.
        View in: PubMed
      356. Rellahan BL, Bluestone JA, Houlden BA, Cotterman MM, Matis LA. Junctional sequences influence the specificity of gamma/delta T cell receptors. J Exp Med. 1991 Feb 1; 173(2):503-6.
        View in: PubMed
      357. Woodle ES, Thistlethwaite JR, Jolliffe LK, Ghobrial I, Fuccello AJ, Stuart FP, Bluestone JA. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc. 1991 Feb; 23(1 Pt 1):81-2.
        View in: PubMed
      358. Houlden BA, Widacki SM, Bluestone JA. Signal transduction through class I MHC by a monoclonal antibody that detects multiple murine and human class I molecules. J Immunol. 1991 Jan 15; 146(2):425-30.
        View in: PubMed
      359. Barrett TA, Hedrick SM, Dent AL, Delvy ML, Kennedy DM, Matis LA, Bluestone JA. Control of self-reactivity in the intestine. Immunol Res. 1991; 10(3-4):341-8.
        View in: PubMed
      360. Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T. Selection of V delta+ T cell receptors of intestinal intraepithelial lymphocytes is dependent on class II histocompatibility antigen expression. Curr Top Microbiol Immunol. 1991; 173:255-67.
        View in: PubMed
      361. Bluestone JA, Cron RQ, Rellahan B, Matis LA. Ligand specificity and repertoire development of murine TCR gamma delta cells. Curr Top Microbiol Immunol. 1991; 173:133-9.
        View in: PubMed
      362. Ellenhorn JD, Woodle ES, Thistlethwaite JR, Bluestone JA. T lymphocyte activation following OKT3 treatment. Curr Surg. 1990 Nov-Dec; 47(6):458-9.
        View in: PubMed
      363. Shimada S, Caughman SW, Bluestone JA, Cron RQ, Owen FL, Smith JA, Katz SI. Freshly isolated Thy-1+ dendritic epidermal cells express T cell receptor gamma delta-CD3. J Dermatol Sci. 1990 Nov; 1(6):459-64.
        View in: PubMed
      364. Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T. Extrathymic selection of TCR gamma delta + T cells by class II major histocompatibility complex molecules. Cell. 1990 Oct 19; 63(2):333-40.
        View in: PubMed
      365. Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, Landais P, Bluestone J, Bach JF, Chatenoud L. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation. 1990 Oct; 50(4):642-8.
        View in: PubMed
      366. Ellenhorn JD, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation. 1990 Oct; 50(4):608-12.
        View in: PubMed
      367. Kast WM, Bluestone JA, Heemskerk MH, Spaargaren J, Voordouw AC, Ellenhorn JD, Melief CJ. Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells. J Immunol. 1990 Oct 1; 145(7):2254-9.
        View in: PubMed
      368. Ezquerra A, Cron RQ, McConnell TJ, Valas RB, Bluestone JA, Coligan JE. T cell receptor delta-gene expression and diversity in the mouse spleen. J Immunol. 1990 Sep 1; 145(5):1311-7.
        View in: PubMed
      369. Bluestone JA, Matis LA. Are TCR alpha beta cells and TCR gamma delta cells that different? Res Immunol. 1990 Sep; 141(7):606-10.
        View in: PubMed
      370. Hunt HD, Pullen JK, Dick RF, Bluestone JA, Pease LR. Structural basis of Kbm8 alloreactivity. Amino acid substitutions on the beta-pleated floor of the antigen recognition site. J Immunol. 1990 Sep 1; 145(5):1456-62.
        View in: PubMed
      371. Richards JM, Vogelzang NJ, Bluestone JA. Neurotoxicity after treatment with muromonab-CD3. N Engl J Med. 1990 Aug 16; 323(7):487-8.
        View in: PubMed
      372. Ferran C, Bluestone J, Bach JF, Chatenoud L. In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody. Transplant Proc. 1990 Aug; 22(4):1922-3.
        View in: PubMed
      373. Ferrick DA, Chan A, Rahemtulla A, Widacki SM, Xia M, Broughton H, Gajewski DA, Ballhausen W, Allison JP, Bluestone JA, et al. Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development. J Immunol. 1990 Jul 1; 145(1):20-7.
        View in: PubMed
      374. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 1990 Jun; 49(6):1117-23.
        View in: PubMed
      375. Ellenhorn JD, Schreiber H, Bluestone JA. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. J Immunol. 1990 Apr 1; 144(7):2840-6.
        View in: PubMed
      376. Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol. 1990 Mar; 20(3):509-15.
        View in: PubMed
      377. Dent AL, Matis LA, Hooshmand F, Widacki SM, Bluestone JA, Hedrick SM. Self-reactive gamma delta T cells are eliminated in the thymus. Nature. 1990 Feb 22; 343(6260):714-9.
        View in: PubMed
      378. Grusby MJ, Nabavi N, Wong H, Dick RF, Bluestone JA, Schotz MC, Glimcher LH. Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase. Cell. 1990 Feb 9; 60(3):451-9.
        View in: PubMed
      379. Cron RQ, Coligan JE, Bluestone JA. Polymorphisms and diversity of T-cell receptor-gamma proteins expressed in mouse spleen. Immunogenetics. 1990; 31(4):220-8.
        View in: PubMed
      380. Cron RQ, Ezquerra A, Coligan JE, Houlden BA, Bluestone JA, Maloy WL. Identification of distinct T cell receptor (TCR)-gamma delta heterodimers using an anti-TCR-gamma variable region serum. J Immunol. 1989 Dec 1; 143(11):3769-75.
        View in: PubMed
      381. Matis LA, Fry AM, Cron RQ, Cotterman MM, Dick RF, Bluestone JA. Structure and specificity of a class II MHC alloreactive gamma delta T cell receptor heterodimer. Science. 1989 Aug 18; 245(4919):746-9.
        View in: PubMed
      382. Hirsch R, Gress RE, Bluestone JA. Anti-CD3 antibody for autoimmune disease, a cautionary note. Lancet. 1989 Jun 17; 1(8651):1390.
        View in: PubMed
      383. Cron RQ, Gajewski TF, Sharrow SO, Fitch FW, Matis LA, Bluestone JA. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells. J Immunol. 1989 Jun 1; 142(11):3754-62.
        View in: PubMed
      384. Hirsch R, Chatenoud L, Gress RE, Sachs DH, Bach JF, Bluestone JA. Suppression of the humoral response to anti-CD3 monoclonal antibody. Transplantation. 1989 May; 47(5):853-7.
        View in: PubMed
      385. Bluestone JA, Matis LA. TCR gamma delta cells--minor redundant T cell subset or specialized immune system component? J Immunol. 1989 Mar 15; 142(6):1785-8.
        View in: PubMed
      386. Hirsch R, Chatenoud L, Gress RE, Bach JF, Sachs DH, Bluestone JA. Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB. Transplant Proc. 1989 Feb; 21(1 Pt 1):1015-6.
        View in: PubMed
      387. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol. 1989 Feb 1; 142(3):737-43.
        View in: PubMed
      388. Ellenhorn JD, Hirsch R, Hartley JP, Bluestone JA. Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3. Transplant Proc. 1989 Feb; 21(1 Pt 1):1013-4.
        View in: PubMed
      389. Evavold BD, Yokoyama A, Hirsch R, Bluestone JA, Quintans J. T helper 2 (Th2) but not Th1 clones co-stimulate resting T cells in the presence of anti-CD3 monoclonal antibody. Int Immunol. 1989; 1(4):443-9.
        View in: PubMed
      390. Bluestone JA, Potter T. T cell clones and monoclonal antibodies: immunologic probes of major histocompatibility complex class I molecules. Chem Immunol. 1989; 46:23-48.
        View in: PubMed
      391. Houlden BA, Matis LA, Cron RQ, Widacki SM, Brown GD, Pampeno C, Meruelo D, Bluestone JA. A TCR gamma delta cell recognizing a novel TL-encoded gene product. Cold Spring Harb Symp Quant Biol. 1989; 54 Pt 1:45-55.
        View in: PubMed
      392. Houlden BA, Cron RQ, Coligan JE, Bluestone JA. Systematic development of distinct T cell receptor-gamma delta T cell subsets during fetal ontogeny. J Immunol. 1988 Dec 1; 141(11):3753-9.
        View in: PubMed
      393. Bluestone JA, Cron RQ, Cotterman M, Houlden BA, Matis LA. Structure and specificity of T cell receptor gamma/delta on major histocompatibility complex antigen-specific CD3+, CD4-, CD8- T lymphocytes. J Exp Med. 1988 Nov 1; 168(5):1899-916.
        View in: PubMed
      394. Ellenhorn JD, Hirsch R, Schreiber H, Bluestone JA. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 1988 Oct 28; 242(4878):569-71.
        View in: PubMed
      395. Cron RQ, Koning F, Maloy WL, Pardoll D, Coligan JE, Bluestone JA. Peripheral murine CD3+, CD4-, CD8- T lymphocytes express novel T cell receptor gamma delta structures. J Immunol. 1988 Aug 15; 141(4):1074-82.
        View in: PubMed
      396. Weiner DB, Liu J, Hanna N, Bluestone JA, Coligan JE, Williams WV, Greene MI. CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibitory cells. Proc Natl Acad Sci U S A. 1988 Aug; 85(16):6077-81.
        View in: PubMed
      397. Lewis J, Foo M, Geier SS, Kumar PA, Nathenson SG, Bluestone JA. Cytotoxic T lymphocyte recognition of novel allodeterminants expressed on in vitro selected H-2Kb mutants. J Immunol. 1988 Aug 1; 141(3):728-35.
        View in: PubMed
      398. Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG. Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor. Cell. 1988 Jul 1; 54(1):47-56.
        View in: PubMed
      399. Leo O, Foo M, Forman J, Shivakumar S, Rabinowitz R, Bluestone JA. Selective expression of the Ly-6C.2 epitope on Lyt-2+ T cells that can develop in the absence of thymic influence. J Immunol. 1988 Jul 1; 141(1):37-44.
        View in: PubMed
      400. Pardoll DM, Fowlkes BJ, Lew AM, Maloy WL, Weston MA, Bluestone JA, Schwartz RH, Coligan JE, Kruisbeek AM. Thymus-dependent and thymus-independent developmental pathways for peripheral T cell receptor-gamma delta-bearing lymphocytes. J Immunol. 1988 Jun 15; 140(12):4091-6.
        View in: PubMed
      401. Maziarz RT, Burakoff SJ, Bluestone JA. The alpha-3 domain of class I MHC proteins influences cytotoxic T lymphocyte recognition of antigenic determinants located within the alpha-1 and alpha-2 domains. J Immunol. 1988 Jun 15; 140(12):4372-7.
        View in: PubMed
      402. Hirsch R, Eckhaus M, Auchincloss H, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol. 1988 Jun 1; 140(11):3766-72.
        View in: PubMed
      403. Tentori L, Pardoll DM, Zuñiga JC, Hu-Li J, Paul WE, Bluestone JA, Kruisbeek AM. Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. J Immunol. 1988 Feb 15; 140(4):1089-94.
        View in: PubMed
      404. Mercep M, Bluestone JA, Noguchi PD, Ashwell JD. Inhibition of transformed T cell growth in vitro by monoclonal antibodies directed against distinct activating molecules. J Immunol. 1988 Jan 1; 140(1):324-35.
        View in: PubMed
      405. Hirsch R, Ellenhorn JD, Bluestone JA. In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth. Princess Takamatsu Symp. 1988; 19:237-43.
        View in: PubMed
      406. Shinohara N, Hozumi N, Watanabe M, Bluestone JA, Johnson-Leva R, Sachs DH. Class II antigen-specific murine cytolytic T lymphocytes (CTL). II. Genuine class II specificity of Lyt-2+ CTL clones. J Immunol. 1988 Jan 1; 140(1):30-6.
        View in: PubMed
      407. Langlet C, Guimezanes A, Kaldy P, Boyer C, Buferne M, Poenie M, Tsien R, Leo O, Bluestone J, Leserman L, et al. Role of Ti/CD3, Thy-1, and Ly-6 in cytolytic T-cell activation analyzed with Ti loss variants. Ann N Y Acad Sci. 1988; 532:33-43.
        View in: PubMed
      408. Singer DS, Ehrlich R, Satz L, Frels W, Bluestone J, Hodes R, Rudikoff S. Structure and expression of class I MHC genes in the miniature swine. Vet Immunol Immunopathol. 1987 Dec; 17(1-4):211-21.
        View in: PubMed
      409. Leo O, Foo M, Henkart PA, Perez P, Shinohara N, Segal DM, Bluestone JA. Role of accessory molecules in signal transduction of cytolytic T lymphocyte by anti-T cell receptor and anti-Ly-6.2C monoclonal antibodies. J Immunol. 1987 Dec 1; 139(11):3556-63.
        View in: PubMed
      410. Matis LA, Cron R, Bluestone JA. Major histocompatibility complex-linked specificity of gamma delta receptor-bearing T lymphocytes. Nature. 1987 Nov 19-25; 330(6145):262-4.
        View in: PubMed
      411. Samelson LE, O'Shea JJ, Luong H, Ross P, Urdahl KB, Klausner RD, Bluestone J. T cell antigen receptor phosphorylation induced by an anti-receptor antibody. J Immunol. 1987 Oct 15; 139(8):2708-14.
        View in: PubMed
      412. Potter TA, Bluestone JA, Rajan TV. A single amino acid substitution in the alpha 3 domain of an H-2 class I molecule abrogates reactivity with CTL. J Exp Med. 1987 Oct 1; 166(4):956-66.
        View in: PubMed
      413. Klausner RD, O'Shea JJ, Luong H, Ross P, Bluestone JA, Samelson LE. T cell receptor tyrosine phosphorylation. Variable coupling for different activating ligands. J Biol Chem. 1987 Sep 15; 262(26):12654-9.
        View in: PubMed
      414. Leo O, Foo M, Segal DM, Shevach E, Bluestone JA. Activation of murine T lymphocytes with monoclonal antibodies: detection on Lyt-2+ cells of an antigen not associated with the T cell receptor complex but involved in T cell activation. J Immunol. 1987 Aug 15; 139(4):1214-22.
        View in: PubMed
      415. Bluestone JA, Pescovitz MD, Frels WI, Singer DS, Hodes RJ. Cytotoxic T lymphocyte recognition of a xenogeneic major histocompatibility complex antigen expressed in transgenic mice. Eur J Immunol. 1987 Jul; 17(7):1035-41.
        View in: PubMed
      416. Stingl G, Koning F, Yamada H, Yokoyama WM, Tschachler E, Bluestone JA, Steiner G, Samelson LE, Lew AM, Coligan JE, et al. Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain. Proc Natl Acad Sci U S A. 1987 Jul; 84(13):4586-90.
        View in: PubMed
      417. Yokoyama WM, Koning F, Stingl G, Bluestone JA, Coligan JE, Shevach EM. Production of a T cell hybridoma that expresses the T cell receptor gamma/delta heterodimer. J Exp Med. 1987 Jun 1; 165(6):1725-30.
        View in: PubMed
      418. Pardoll DM, Fowlkes BJ, Bluestone JA, Kruisbeek A, Maloy WL, Coligan JE, Schwartz RH. Differential expression of two distinct T-cell receptors during thymocyte development. Nature. 1987 Mar 5-11; 326(6108):79-81.
        View in: PubMed
      419. Bluestone JA, Pardoll D, Sharrow SO, Fowlkes BJ. Characterization of murine thymocytes with CD3-associated T-cell receptor structures. Nature. 1987 Mar 5-11; 326(6108):82-4.
        View in: PubMed
      420. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A. 1987 Mar; 84(5):1374-8.
        View in: PubMed
      421. Takayama H, Trenn G, Humphrey W, Bluestone JA, Henkart PA, Sitkovsky MV. Antigen receptor-triggered secretion of a trypsin-type esterase from cytotoxic T lymphocytes. J Immunol. 1987 Jan 15; 138(2):566-9.
        View in: PubMed
      422. Bluestone JA. Analysis of structure/function relationships among major histocompatibility complex class I antigens. Immunol Res. 1987; 6(1-2):67-79.
        View in: PubMed
      423. Pardoll DM, Lew AM, Maloy WL, Fowlkes BJ, Kruisbeek A, Bluestone JA, Schwartz RH, Coligan JE. Analysis of T-cell receptor gamma chain expression in the thymus. Adv Exp Med Biol. 1987; 225:241-6.
        View in: PubMed
      424. McCluskey J, Boyd L, Foo M, Forman J, Margulies DH, Bluestone JA. Analysis of hybrid H-2D and L antigens with reciprocally mismatched aminoterminal domains: functional T cell recognition requires preservation of fine structural determinants. J Immunol. 1986 Dec 15; 137(12):3881-90.
        View in: PubMed
      425. Leo O, Sachs DH, Samelson LE, Foo M, Quinones R, Gress R, Bluestone JA. Identification of monoclonal antibodies specific for the T cell receptor complex by Fc receptor-mediated CTL lysis. J Immunol. 1986 Dec 15; 137(12):3874-80.
        View in: PubMed
      426. Lew AM, Pardoll DM, Maloy WL, Fowlkes BJ, Kruisbeek A, Cheng SF, Germain RN, Bluestone JA, Schwartz RH, Coligan JE. Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. Science. 1986 Dec 12; 234(4782):1401-5.
        View in: PubMed
      427. Ting CC, Bluestone JA, Hargrove ME, Loh NN. Expression and function of asialo GM1 in alloreactive cytotoxic T lymphocytes. J Immunol. 1986 Oct 1; 137(7):2100-6.
        View in: PubMed
      428. Bluestone JA, Langlet C, Geier SS, Nathenson SG, Foo M, Schmitt-Verhulst AM. Somatic cell variants express altered H-2Kb allodeterminants recognized by cytolytic T cell clones. J Immunol. 1986 Aug 15; 137(4):1244-50.
        View in: PubMed
      429. Lynch DH, Cole BC, Bluestone JA, Hodes RJ. Cross-reactive recognition by antigen-specific, major histocompatibility complex-restricted T cells of a mitogen derived from Mycoplasma arthritidis is clonally expressed and I-E restricted. Eur J Immunol. 1986 Jul; 16(7):747-51.
        View in: PubMed
      430. Ildstad ST, Bluestone JA, Sachs DH. Alloresistance to engraftment of allogeneic donor bone marrow is mediated by an Lyt-2+ T cell in mixed allogeneic reconstitution (C57BL/10Sn + B10.D2/nSn----C57BL/10Sn). J Exp Med. 1986 May 1; 163(5):1343-8.
        View in: PubMed
      431. Bluestone JA, Leo O, Epstein SL, Sachs DH. Idiotypic manipulation of the immune response to transplantation antigens. Immunol Rev. 1986 Apr; 90:5-27.
        View in: PubMed
      432. Shinohara N, Bluestone JA, Sachs DH. Cloned cytotoxic T lymphocytes that recognize an I-A region product in the context of a class I antigen. J Exp Med. 1986 Apr 1; 163(4):972-80.
        View in: PubMed
      433. McCluskey J, Bluestone JA, Coligan JE, Maloy WL, Margulies DH. Serologic and T cell recognition of truncated transplantation antigens encoded by in vitro deleted class I major histocompatibility genes. J Immunol. 1986 Feb 15; 136(4):1472-81.
        View in: PubMed
      434. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10). J Immunol. 1986 Jan; 136(1):28-33.
        View in: PubMed
      435. Rabinowitz R, Bluestone JA, Sachs DH. Evidence for a regulatory idiotypic network in the in vivo response to H-2 antigens. J Exp Med. 1985 Aug 1; 162(2):745-55.
        View in: PubMed
      436. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med. 1985 Jul 1; 162(1):231-44.
        View in: PubMed
      437. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985 Jul 25-31; 316(6026):354-6.
        View in: PubMed
      438. Hoffman RW, Bluestone JA, Leo O, Shaw S. Lysis of anti-T3-bearing murine hybridoma cells by human allospecific cytotoxic T cell clones and inhibition of that lysis by anti-T3 and anti-LFA-1 antibodies. J Immunol. 1985 Jul; 135(1):5-8.
        View in: PubMed
      439. Bluestone JA, Foo M, Allen H, Segal D, Flavell RA. Allospecific cytolytic T lymphocytes recognize conformational determinants on hybrid mouse transplantation antigens. J Exp Med. 1985 Jul 1; 162(1):268-81.
        View in: PubMed
      440. Golding H, Bluestone J, Satz ML, Singer D, Singer A. Generation of primary murine CTL specific for allogeneic and xenogeneic MHC determinants upon stimulation with murine L cells transfected with class I genes. J Immunol. 1985 Jun; 134(6):3557-9.
        View in: PubMed
      441. Frels WI, Bluestone JA, Hodes RJ, Capecchi MR, Singer DS. Expression of a microinjected porcine class I major histocompatibility complex gene in transgenic mice. Science. 1985 May 3; 228(4699):577-80.
        View in: PubMed
      442. Levy RB, Ozato K, Richardson JC, Bluestone JA. Molecular localization of allogeneic and self determinants recognized by bulk and clonal populations of cytotoxic T cells. J Immunol. 1985 Feb; 134(2):677-83.
        View in: PubMed
      443. Henkart P, Henkart M, Millard P, Frederikse P, Bluestone J, Blumenthal R, Yue C, Reynolds C. The role of cytoplasmic granules in cytotoxicity by large granular lymphocytes and cytotoxic T lymphocytes. Adv Exp Med Biol. 1985; 184:121-38.
        View in: PubMed
      444. Perez P, Bluestone JA, Stephany DA, Segal DM. Quantitative measurements of the specificity and kinetics of conjugate formation between cloned cytotoxic T lymphocytes and splenic target cells by dual parameter flow cytometry. J Immunol. 1985 Jan; 134(1):478-85.
        View in: PubMed
      445. Bluestone JA, Potter TA, Chatterjee-Hasrouni S, Rajan TV. CTL recognize different determinants from those defined serologically on Ld somatic cell mutants. J Immunol. 1984 Sep; 133(3):1168-73.
        View in: PubMed
      446. Bluestone JA, Auchincloss H, Sachs DH, Fibi M, Hämmerling GJ. Anti-idiotypes against anti-H-2 antibodies VI. Detection of shared idiotypes among monoclonal anti-H-2 antibodies. Eur J Immunol. 1983 Jun; 13(6):489-95.
        View in: PubMed
      447. Auchincloss H, Bluestone JA, Sachs DH. Antiidiotypes against anti-H-2 monoclonal antibodies. V. In vivo antiidiotype treatment induces idiotype-specific helper T cells. J Exp Med. 1983 Apr 1; 157(4):1273-86.
        View in: PubMed
      448. Ozato K, Epstein SL, Bluestone JA, Sharrow SO, Hansen T, Sachs DH. The presence of a common idiotype in anti-H-2 immune sera as detected by anti-idiotype to a monoclonal anti-H-2 antibody. Eur J Immunol. 1983 Jan; 13(1):13-8.
        View in: PubMed
      449. Bluestone JA, Lopez C. Suppression of the immune response in tumor-bearing mice. III. Induction of functionally suppressive antigen-driven macrophages. Cancer Invest. 1983; 1(1):5-13.
        View in: PubMed
      450. Sachs DH, Bluestone JA, Epstein SL, Rabinowitz R. Idiotypes of anti-major histocompatibility complex antibodies. Ann N Y Acad Sci. 1983; 418:265-71.
        View in: PubMed
      451. Bluestone JA, Krutzsch HC, Auchincloss H, Cazenave PA, Kindt TJ, Sachs DH. Anti-idiotypes against anti-H-2 monoclonal antibodies: structural analysis of the molecules induced by in vivo anti-idiotype treatment. Proc Natl Acad Sci U S A. 1982 Dec; 79(24):7847-51.
        View in: PubMed
      452. Bluestone JA, Auchincloss H, Cazenave PA, Ozato K, Sachs DH. Anti-idiotypes to monoclonal anti-H-2 antibodies. III. Syngeneic anti-idiotypes on antibodies induced by in vivo administration of xenogeneic anti-idiotypes. J Immunol. 1982 Nov; 129(5):2066-8.
        View in: PubMed
      453. Bluestone JA, Lopez C. Induction of gp70-specific suppressor T-cells in mice inoculated with virus-producing tumor cells. J Natl Cancer Inst. 1982 Oct; 69(4):953-9.
        View in: PubMed
      454. Epstein SL, Masakowski VR, Sharrow SO, Bluestone JA, Ozato K, Sachs DH. Idiotypes of anti-Ia antibodies. II. Effects of in vivo treatment with xenogeneic anti-idiotype. J Immunol. 1982 Oct; 129(4):1545-52.
        View in: PubMed
      455. Bluestone JA, Metzger JJ, Knode MC, Ozato K, Sachs DH. Anti-idiotypes to monoclonal anti-H-2 antibodies--I. Contribution of isolated heavy and light chains to idiotype expression. Mol Immunol. 1982 Apr; 19(4):515-24.
        View in: PubMed
      456. Bluestone JA, Epstein SL, Ozato K, Sharrow SO, Sachs DH. Anti-idiotypes to monoclonal anti-H-2 antibodies. II. Expression of anti-H-2Kk idiotypes on antibodies induced by anti-idiotype or H-2Kk antigen. J Exp Med. 1981 Nov 1; 154(5):1305-18.
        View in: PubMed
      457. Bluestone JA, Lopez C, Hurtenbach U. Mixed lymphocyte reactivity in spleen cells from F-9 tumor-bearing ice. I. Suppressor cell induction and characterization. Cell Immunol. 1981 Aug; 62(2):334-40.
        View in: PubMed
      458. Hurtenbach U, Bennett D, Bluestone JA. Mixed lymphocyte reactivity in spleen cells from F-9 tumor-bearing mice. II. Functional cross-reactivity between F-9 cells and testicular cells. Cell Immunol. 1981 Aug; 62(2):341-9.
        View in: PubMed
      459. Epstein SL, Ozato K, Bluestone JA, Sachs DH. Idiotypes of anti-Ia antibodies. I. Expression of the 14-4-4S idiotype in humoral immune responses. J Exp Med. 1981 Aug 1; 154(2):397-409.
        View in: PubMed
      460. Bluestone JA, Sharrow SO, Epstein SL, Ozato K, Sachs DH. Induction of anti-H-2 antibodies without alloantigen exposure by in vivo administration of anti-idiotype. Nature. 1981 May 21; 291(5812):233-5.
        View in: PubMed
      461. Sachs DH, Bluestone JA, Epstein SL, Ozato K. Antiidiotypes to monoclonal anti-H-2 and anti-Ia hybridoma antibodies. Transplant Proc. 1981 Mar; 13(1 Pt 2):953-7.
        View in: PubMed
      462. Bluestone JA, Lopez C. Suppression of the immune response in tumor-bearing mice. I. Response to virus-producing tumor cells and non-virus-producing tumor cells. J Natl Cancer Inst. 1979 Nov; 63(5):1215-20.
        View in: PubMed
      463. Bluestone JA, Lopez C. Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells. J Natl Cancer Inst. 1979 Nov; 63(5):1221-7.
        View in: PubMed
      Jeffrey's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Same Department
      Back to TOP